Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  MUMBAI STOCK EXCHANGE  >  Dr. Reddy's Laboratories Limited    500124   INE089A01023

DR. REDDY'S LABORATORIES LIMITED

(500124)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Sensex, Nifty end lower as banks drop; pharma shines

share with twitter share with LinkedIn share with facebook
09/18/2020 | 07:58am EDT
People walk past the Bombay Stock Exchange building in Mumbai

Indian shares gave up early gains to end lower on Friday as banking stocks fell in afternoon trading, with HDFC Bank closing at a month's low, although a jump in pharma stocks capped losses on the Nifty.

The blue-chip NSE Nifty 50 index closed 0.1% lower at 11,504.95, while the benchmark S&P BSE Sensex, which has fewer pharma components, ended down 0.34% at 38,845.82.

The Nifty ended the week 0.4% higher, while the Sensex closed a tad lower.

The Nifty Bank Index finished 1.3% lower at its worst closing level in a month, capping its third straight week of losses, dragged by a 2.4% slide in top private-sector lender HDFC Bank.

The Nifty Pharma index clocked its best day since Aug. 10, closing up 5%, as drugmaker Dr.Reddy's Laboratories Ltd added 10.5% to close at a record high.

The pharmaceutical firm settled a patent litigation with U.S. drugmaker Bristol-Myers Squibb Co over the cancer treatment Revlimid, prompting analyst upgrades to its stock.

Drugmakers Lupin Ltd and Cipla Ltd jumped 4.7% and 7.3%, respectively, after U.S.-listed Perrigo Company Plc issued a U.S. nationwide recall of its albuterol sulfate inhalation aerosol product due to complaints of clogging issues.

Cipla and Lupin have their own versions of the aerosol product approved by the U.S. FDA.

Investor sentiment in broader markets was also tepid on worries over a resurgence in coronavirus cases and disappointment that central banks merely affirmed their monetary support this week, without promising new stimulus.

(Reporting by Anuron Kumar Mitra in Bengaluru; Editing by Ramakrishnan M.)


Stocks mentioned in the article
ChangeLast1st jan.
DR. REDDY'S LABORATORIES LIMITED -0.15% 5015.9 End-of-day quote.74.34%
NIFTY 50 0.06% 11937.4 Delayed Quote.-1.96%
NIFTY BANK -0.02% 24525.8 Delayed Quote.-23.89%
PERRIGO COMPANY PLC 0.31% 45.62 Delayed Quote.-11.69%
SENSEX 30 0.31% 40685.5 Real-time Quote.-1.38%
share with twitter share with LinkedIn share with facebook
All news about DR. REDDY'S LABORATORIES LIMITED
10/22Dr Reddy's isolates data center services after cyberattack
RE
10/22DR REDDY LABORATORIES : Data breach prompts India's Dr Reddy's to shut key plant..
RE
10/22Fujifilm partners Shanghai firm to seek China COVID-19 approval for Avigan
RE
10/22Fujifilm partners Shanghai firm to seek China COVID-19 approval for Avigan
RE
10/21DR REDDY LABORATORIES : . Reddy's announces the re-launch of over-the-counter Fa..
AQ
10/20DR REDDY LABORATORIES : . Reddy's announces the re-launch of over-the-counter Fa..
BU
10/19Fujifilm seeks approval for Avigan as COVID-19 treatment in Japan
RE
10/18SERUM INSTITUTE, BHARAT BIOTECH TO B : Vardhan
RE
10/17DR REDDY LABORATORIES : . Reddy's and RDIF receive approval to conduct clinical ..
BU
10/17DR REDDY LABORATORIES : Russia receives renewed approval for COVID-19 vaccine tr..
RE
More news
Financials
Sales 2021 191 B 2 588 M 2 588 M
Net income 2021 26 076 M 353 M 353 M
Net cash 2021 8 440 M 114 M 114 M
P/E ratio 2021 32,0x
Yield 2021 0,51%
Capitalization 832 B 11 272 M 11 264 M
EV / Sales 2021 4,31x
EV / Sales 2022 3,75x
Nbr of Employees 21 650
Free-Float 69,0%
Chart DR. REDDY'S LABORATORIES LIMITED
Duration : Period :
Dr. Reddy's Laboratories Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DR. REDDY'S LABORATORIES LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 33
Average target price 5 162,81 INR
Last Close Price 5 015,90 INR
Spread / Highest target 28,6%
Spread / Average Target 2,93%
Spread / Lowest Target -26,2%
EPS Revisions
Managers
NameTitle
Erez Israeli Chief Executive & Operating Officer
Saumen Chakraborty President, CFO & Global Head-IT
Satish Kallam Reddy Co-Chairman
Gunupati Venkateswara Prasad Co-Chairman & Managing Director
Kalpana Jaisingh Morparia Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
DR. REDDY'S LABORATORIES LIMITED74.34%11 272
JOHNSON & JOHNSON-0.43%382 350
ROCHE HOLDING AG-5.29%280 884
PFIZER INC.-2.55%212 162
MERCK & CO., INC.-12.23%201 909
NOVARTIS AG-16.78%185 999